Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum

Frontiers of Medicine

Volumn 9, Issue 4, 2015, Pages 457-467

  Wang, Jiabo ^a   Ma, Zhijie ^a,b   Niu, Ming ^a   Zhu, Yun ^a   Liang, Qingsheng ^a   Zhao, Yanling ^a   Song, Jingyuan ^c   Bai, Zhaofang ^a   Zhang, Yaming ^a   Zhang, Ping ^a   Li, Na ^a   Meng, Yakun ^a   Li, Qi ^a   Qin, Lushan ^a   Teng, Guangju ^a   Cao, Junling ^d   Li, Baosen ^a   Chen, Shilin ^c   Li, Yonggang ^a   Zou, Zhengsheng ^a   Zhou, Honghao ^e   Xiao, Xiaohe ^a   more..

^a 302 MILITARY HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^d BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chinese herbal medicine; drug induced liver injury; metabolomics; pharmacognosy; Polygonum multiflorum; stilbene

Indexed keywords

HERBACEOUS AGENT; STILBENE DERIVATIVE;

ADVERSE EFFECTS; CHEMISTRY; CHINESE MEDICINE; DRUG-INDUCED LIVER INJURY; FALLOPIA MULTIFLORA; HUMAN; LIVER FUNCTION TEST; METABOLISM; METABOLOME; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT;

DRUG-INDUCED LIVER INJURY; DRUGS, CHINESE HERBAL; FALLOPIA MULTIFLORA; HUMANS; LIVER FUNCTION TESTS; MEDICINE, CHINESE TRADITIONAL; METABOLOME; RISK ASSESSMENT; STILBENES;

EID: 84973867655     PISSN: 20950217     EISSN: 20950225     Source Type: Journal    
DOI: 10.1007/s11684-015-0417-8     Document Type: Article

References (42)

1. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014; 109(7): 950–966, quiz 967
2. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46(11): 1323–1330
3. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26(3): 664–669
4. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, Fontana RJ, Hayashi PH; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51(6): 2117–2126
5. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48(4): 1175–1183
6. Barritt AS, Lee J, Hayashi PH. Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepato, 2010, 8(7): 635–637
7. de Smet PA. Herbal medicine in Europe—relaxing regulatory standards. N Engl J Med 2005; 352(12): 1176–1178
8. Teschke R, Eickhoff A, Wolff A, Frenzel C, Schulze J. Herbal hepatotoxicity and WHO global introspection method. Ann Hepatol 2013; 12(1): 11–21
9. Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity—challenges and pitfalls of causality assessment. Maturitas 2009; 63(4): 302–314
10. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause 2010; 17(2): 426–440
11. Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012; 63(1): 1–9
12. Teschke R, Schmidt-Taenzer W, Wolff A. USP suspected herbal hepatotoxicity: quality of causality assessment is more important than quantity of counted cases, not vice versa. Pharmocoepidemiol Drug Saf 2012; 21(3): 336–338
13. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425(6954): 191–196
14. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, e SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013; 339(6124): 1216–1219
15. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, Kroemer G. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis 2010; 1(1): e10
16. Wang JB, Xiao XH, Du XX, Zou ZS, Song HB, Guo XX. Identification and early diagnosis for traditional Chinese medicineinduced liver injury based on translational toxicology. Zhongguo Zhong Yao Za Zhi 2014; 39(1): 5–9 (in Chinese)
17. Wang J, Zou Z, Zhao Y, Qin L, Li Q, Ma Z, Du X, Xiao X. Metabonomic biomarkers for drug-induced liver injury in rats and humans: better than alanine aminotransferase? Hepatology 2013; 58 (4): A379–A380
18. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16(6): 1246–1252
19. Xiaojing W, Liang Z, Chen HB, Zhao Z, Li P. Identification of Daqingye and Banlangen including crude drugs and decoction dregs from three plant species by normal light and fluorescence microscopy. Microsc Res Tech 2013; 76(8): 774–782
20. Chen S, Xu J, Liu C, Zhu Y, Nelson DR, Zhou S, Li C,Wang L, Guo X, Sun Y, Luo H, Li Y, Song J, Henrissat B, Levasseur A, Qian J, Li J, Luo X, Shi L, He L, Xiang L, Xu X, Niu Y, Li Q, Han MV, Yan H, Zhang J, Chen H, Lv A, Wang Z, Liu M, Schwartz DC, Sun C. Genome sequence of the model medicinal mushroom Ganoderma lucidum. Nat Commun 2012; 3: 913
21. Qiu X, Zhang J, Huang Z, Zhu D, Xu W. Profiling of phenolic constituents in Polygonum multiflorum Thunb. by combination of ultra-high-pressure liquid chromatography with linear ion trap- Orbitrap mass spectrometry. J Chromatogr A 2013; 1292: 121–131
22. The State Pharmacopoeia Commission of PR China. First Div., Appendix XID. Pharmacopoeia of the People’s Republic of China. Beijing: Chemical Industry Press, 2010: Appendix 67
23. Chen X, Bian Z, Hou H, Yang F, Liu S, Tang G, Hu Q. Development and validation of a method for the determination of 159 pesticide residues in tobacco by gas chromatography-tandem mass spectrometry. J Agric Food Chem 2013; 61(24): 5746–5757
24. Dalton HR, Fellows HJ, Stableforth W, Joseph M, Thurairajah PH, Warshow U, Hazeldine S, Remnarace R, Ijaz S, Hussaini SH, Bendall RP. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007; 26(10): 1429–1435
25. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology, 2011, 141: 1665–1672 e1–9
26. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, Dalekos GN, Muratori L. Review article: autoimmune hepatitis — current management and challenges. Aliment Pharmacol Ther 2013; 38(8): 887–913
27. Wang JB, Pu SB, Sun Y, Li ZF, Niu M, Yan XZ, Zhao YL, Wang LF, Qin XM, Ma ZJ, Zhang, YM, Li BS, Luo SQ, Gong M, Sun YQ, Zou ZS, Xiao XH. Metabolomic profiling of autoimmune hepatitis: the diagnostic utility of nuclear magnetic resonance spectroscopy. J Proteome Res 2014; 13(8): 3792–3801
28. Coghlan ML, Haile J, Houston J, Murray DC, White NE, Moolhuijzen P, Bellgard MI, Bunce M. Deep sequencing of plant and animal DNA contained within traditional Chinese medicines reveals legality issues and health safety concerns. PLoS Genet 2012; 8(4): e1002657
29. Gökmen MR, Cosyns JP, Arlt VM, Stiborová M, Phillips DH, Schmeiser HH, Simmonds MS, Cook HT, Vanherweghem JL, Nortier JL, Lord GM. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med 2013; 158(6): 469–477
30. Ma J, Zheng L, Deng T, Li CL, He YS, Li HJ, Li P. Stilbene glucoside inhibits the glucuronidation of emodin in rats through the down-regulation of UDP-glucuronosyltransferases 1A8: application to a drug-drug interaction study in Radix Polygoni Multiflori. J Ethnopharmacol 2013; 147(2): 335–340
31. Wu X, Chen X, Huang Q, Fang D, Li G, Zhang G. Toxicity of raw and processed roots of Polygonum multiflorum. Fitoterapia 2012; 83 (3): 469–475
32. Murias M, Luczak MW, Niepsuj A, Krajka-Kuzniak V, Zielinska- Przyjemska M, Jagodzinski PP, Jäger W, Szekeres T, Jodynis- Liebert J. Cytotoxic activity of 3,3',4,4',5,5'-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol In Vitro 2008; 22(5): 1361–1370
33. Ünsalan O, Kus N, Jarmelo S, Fausto R. Trans- and cis-stilbene isolated in cryogenic argon and xenon matrices. Spectrochim Acta A Mol Biomol Spectrosc 2015: 136(A): 81–94
34. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988; 34(2): 200–208
35. Siles R, Ackley JF, Hadimani MB, Hall JJ, Mugabe BE, Guddneppanavar R, Monk KA, Chapuis JC, Pettit GR, Chaplin DJ, Edvardsen K, Trawick ML, Garner CM, Pinney KG. Combretastatin dinitrogen-substituted stilbene analogues as tubulin- binding and vascular-disrupting agents. J Nat Prod 2008; 71(3): 313–320
36. Sun J, Huang X, Wu H, Huang F. HPLC/IT-MS analysis of glycosides in radix Polygoni multiflori. Nat Prod Res Dev 2009; 21: 806–812
37. Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 2014; 34(2): 172–193
38. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol 2007; 5(4): 408–416
39. Wu X, Chen X, Huang Q, Fang D, Li G, Zhang G. Toxicity of raw and processed roots of Polygonum multiflorum. Fitoterapia 2012; 83 (3): 469–475
40. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49(7): 449–454
41. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci 2004; 82(2): 614–619
42. Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Jacobson E, Gumbleton T, Oakervee H, Cavenagh J. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol 2013; 160(5): 714–717